These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

206 related articles for article (PubMed ID: 22442825)

  • 1. Mechanism-based population modelling of the effects of vildagliptin on GLP-1, glucose and insulin in patients with type 2 diabetes.
    Landersdorfer CB; He YL; Jusko WJ
    Br J Clin Pharmacol; 2012 Mar; 73(3):373-90. PubMed ID: 22442825
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mechanism-based population pharmacokinetic modelling in diabetes: vildagliptin as a tight binding inhibitor and substrate of dipeptidyl peptidase IV.
    Landersdorfer CB; He YL; Jusko WJ
    Br J Clin Pharmacol; 2012 Mar; 73(3):391-401. PubMed ID: 22442826
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with type 2 diabetes.
    He YL; Yamaguchi M; Ito H; Terao S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2010 Sep; 48(9):582-95. PubMed ID: 20860912
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Pharmacokinetic and pharmacodynamic interaction of vildagliptin and voglibose in Japanese patients with Type 2 diabetes.
    Yamaguchi M; Saji T; Mita S; Kulmatycki K; He YL; Furihata K; Sekiguchi K
    Int J Clin Pharmacol Ther; 2013 Aug; 51(8):641-51. PubMed ID: 23782587
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Clinical pharmacokinetics and pharmacodynamics of vildagliptin.
    He YL
    Clin Pharmacokinet; 2012 Mar; 51(3):147-62. PubMed ID: 22339447
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Feedback suppression of meal-induced glucagon-like peptide-1 (GLP-1) secretion mediated through elevations in intact GLP-1 caused by dipeptidyl peptidase-4 inhibition: a randomized, prospective comparison of sitagliptin and vildagliptin treatment.
    Baranov O; Kahle M; Deacon CF; Holst JJ; Nauck MA
    Diabetes Obes Metab; 2016 Nov; 18(11):1100-1109. PubMed ID: 27300579
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Pharmacokinetics and pharmacodynamics of vildagliptin in patients with type 2 diabetes mellitus.
    He YL; Serra D; Wang Y; Campestrini J; Riviere GJ; Deacon CF; Holst JJ; Schwartz S; Nielsen JC; Ligueros-Saylan M
    Clin Pharmacokinet; 2007; 46(7):577-88. PubMed ID: 17596103
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Hormonal and metabolic effects of morning or evening dosing of the dipeptidyl peptidase IV inhibitor vildagliptin in patients with type 2 diabetes.
    He YL; Valencia J; Zhang Y; Schwartz SL; Ligueros-Saylan M; Foley J; Dole WP
    Br J Clin Pharmacol; 2010 Jul; 70(1):34-42. PubMed ID: 20642545
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Inhibition of DPP-4 with vildagliptin improved insulin secretion in response to oral as well as "isoglycemic" intravenous glucose without numerically changing the incretin effect in patients with type 2 diabetes.
    Vardarli I; Nauck MA; Köthe LD; Deacon CF; Holst JJ; Schweizer A; Foley JE
    J Clin Endocrinol Metab; 2011 Apr; 96(4):945-54. PubMed ID: 21239518
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Effects of dipeptidyl peptidase IV inhibition on glycemic, gut hormone, triglyceride, energy expenditure, and energy intake responses to fat in healthy males.
    Heruc GA; Horowitz M; Deacon CF; Feinle-Bisset C; Rayner CK; Luscombe-Marsh N; Little TJ
    Am J Physiol Endocrinol Metab; 2014 Nov; 307(9):E830-7. PubMed ID: 25231186
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Quantification of the Contribution of GLP-1 to Mediating Insulinotropic Effects of DPP-4 Inhibition With Vildagliptin in Healthy Subjects and Patients With Type 2 Diabetes Using Exendin [9-39] as a GLP-1 Receptor Antagonist.
    Nauck MA; Kind J; Köthe LD; Holst JJ; Deacon CF; Broschag M; He YL; Kjems L; Foley J
    Diabetes; 2016 Aug; 65(8):2440-7. PubMed ID: 27207543
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Treatment with the dipeptidyl peptidase-4 inhibitor vildagliptin improves fasting islet-cell function in subjects with type 2 diabetes.
    D'Alessio DA; Denney AM; Hermiller LM; Prigeon RL; Martin JM; Tharp WG; Saylan ML; He Y; Dunning BE; Foley JE; Pratley RE
    J Clin Endocrinol Metab; 2009 Jan; 94(1):81-8. PubMed ID: 18957505
    [TBL] [Abstract][Full Text] [Related]  

  • 13. The effect of dipeptidyl peptidase-4 inhibition on gastric volume, satiation and enteroendocrine secretion in type 2 diabetes: a double-blind, placebo-controlled crossover study.
    Vella A; Bock G; Giesler PD; Burton DB; Serra DB; Saylan ML; Deacon CF; Foley JE; Rizza RA; Camilleri M
    Clin Endocrinol (Oxf); 2008 Nov; 69(5):737-44. PubMed ID: 18331607
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effects of meal timing relative to dosing on the pharmacokinetics and pharmacodynamics of vildagliptin in Japanese patients with Type 2 diabetes.
    He YL; Ito H; Yamaguchi M; Terao S; Shimada S; Irie S; Sekiguchi K
    Int J Clin Pharmacol Ther; 2012 Apr; 50(4):237-47. PubMed ID: 22456294
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacokinetics and pharmacodynamics of vildagliptin in healthy Chinese volunteers.
    Hu P; Yin Q; Deckert F; Jiang J; Liu D; Kjems L; Dole WP; He YL
    J Clin Pharmacol; 2009 Jan; 49(1):39-49. PubMed ID: 18832295
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Inhibition of dipeptidyl peptidase-4 by vildagliptin during glucagon-like Peptide 1 infusion increases liver glucose uptake in the conscious dog.
    Edgerton DS; Johnson KM; Neal DW; Scott M; Hobbs CH; Zhang X; Duttaroy A; Cherrington AD
    Diabetes; 2009 Jan; 58(1):243-9. PubMed ID: 18840785
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Emerging role of dipeptidyl peptidase-IV (DPP-4) inhibitor vildagliptin in the management of type 2 diabetes.
    Kalra S
    J Assoc Physicians India; 2011 Apr; 59():237-45. PubMed ID: 21755761
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Measurements of islet function and glucose metabolism with the dipeptidyl peptidase 4 inhibitor vildagliptin in patients with type 2 diabetes.
    Azuma K; Rádiková Z; Mancino J; Toledo FG; Thomas E; Kangani C; Dalla Man C; Cobelli C; Holst JJ; Deacon CF; He Y; Ligueros-Saylan M; Serra D; Foley JE; Kelley DE
    J Clin Endocrinol Metab; 2008 Feb; 93(2):459-64. PubMed ID: 18042650
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Dipeptidyl-peptidase-IV inhibition augments postprandial lipid mobilization and oxidation in type 2 diabetic patients.
    Boschmann M; Engeli S; Dobberstein K; Budziarek P; Strauss A; Boehnke J; Sweep FC; Luft FC; He Y; Foley JE; Jordan J
    J Clin Endocrinol Metab; 2009 Mar; 94(3):846-52. PubMed ID: 19088168
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Vildagliptin , a DPP-4 inhibitor for the twice-daily treatment of type 2 diabetes mellitus with or without metformin.
    Forst T; Bramlage P
    Expert Opin Pharmacother; 2014 Jun; 15(9):1299-313. PubMed ID: 24837407
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.